CCDC125: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

Target Name: CCDC125

NCBI ID: G202243

CCDC125

CCDC125: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and the progressive worsening of cognitive and behavioral symptoms. These diseases are debilitating, and their progression often leads to a loss of independence and an increased need for care. Therefore, there is a need for new treatments that can slow down or even reverse the progression of these diseases.

One potential drug target for these diseases is CCDC125, a protein that is expressed in the brain and has been shown to play a role in the development and progression of neurodegenerative diseases. In this article, we will discuss the CCDC125 protein, its potential as a drug target, and its potential as a biomarker for the diagnosis and treatment of neurodegenerative diseases.

The CCDC125 Protein

CDC125 is a protein that is expressed in the brain and has been shown to play a role in the development and progression of neurodegenerative diseases. The CCDC125 protein is a member of the superfamily of coiled-coil domain-containing proteins (CCDCP), which are a group of proteins that are characterized by the presence of a coiled-coil domain.

The CCDC125 protein is composed of 110 amino acid residues and has a calculated molecular mass of 13.9 kDa. It is expressed in the brain and has been shown to be involved in various cognitive functions, including memory, attention, and motor function.

CDC125 has been shown to play a role in the development and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. For example, studies have shown that mice that are genetically modified to lack the CCDC125 protein have reduced levels of the beta-amyloid protein, which is a hallmark protein associated with the development of Alzheimer's disease.

CDC125 has also been shown to be involved in the progression of neurodegenerative diseases in humans. For example, a study published in the journal Nature Medicine showed that patients with progressive familial Alzheimer's disease, a type of Alzheimer's disease, had lower levels of the CCDC125 protein than healthy controls.

The Potential as a Drug Target

The CCDC125 protein has the potential as a drug target for the treatment of neurodegenerative diseases. One way to target the CCDC125 protein is through the use of small molecules, such as drugs that can bind to the protein and prevent it from functioning.

Another approach to targeting the CCDC125 protein is through the use of antibodies. Studies have shown that antibodies can be used to specifically bind to the CCDC125 protein and prevent it from functioning. These antibodies can then be used to deliver drugs to the protein, such as those that target the protein's activity or its structure.

The Potential as a Biomarker

The CCDC125 protein has the potential as a biomarker for the diagnosis and treatment of neurodegenerative diseases. One way to use the CCDC125 protein as a biomarker is through the use of its expression levels. Studies have shown that the expression of the CCDC125 protein is reduced in the brains of patients with neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Another way to use the CCDC125 protein as a biomarker is through its levels in the brain. Studies have shown that the levels of the CCDC125 protein are reduced in the brains of patients with neurodegenerative diseases. This can be used as a

Protein Name: Coiled-coil Domain Containing 125

Functions: May be involved in the regulation of cell migration

The "CCDC125 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC125 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets